Jeremy Cobb leverages his technical and industry experience to focus on the representation of life science companies in Hatch-Waxman litigation, traditional patent litigation, post-grant proceedings before the Patent Trial and Appeal Board (PTAB), and general commercial disputes. His experience spans from pre-litigation analysis through appeal for both small molecule and biologic drug products. He also has experience counseling clients on patent portfolio analysis, regulatory exclusivity; and patent term extensions.
Jeremy has represented companies in high-stakes patent and commercial disputes, defending diverse patent portfolios of business critical products. He has held key roles in these matters, including development of case strategy, case management, cross-border discovery, arguing motions, expert reports, depositions, and the examination of fact and expert witnesses at trial.
Prior to becoming an attorney, Jeremy worked as a scientist at GlaxoSmithKline. At GSK, he had exposure to all phases of drug development from drug discovery through product launch, including direct involvement in the development of the commercial synthesis of FDA approved product Potiga.
Experience
- Alexion in a commercial dispute against accusations of breach of contract seeking damages in excess of US$600 million. Shareholder Representative Services v. Alexion Pharmaceuticals, Del. Ch. (20-1069).
- Regeneron in defense of its Eylea® product, a fusion protein used to treat age related macular degeneration, against multiple patent challenges before the PTAB. IPR2021-880, 881; PGR2021-117; IPR2022-1225, 1226; IPR 2023-442.
- Major pharmaceutical company in successfully defending the sale and use of an anti-EGFR monoclonal antibody used to treat squamous cell cancer of the head and neck against accusations of patent infringement. Representation included a successful patent challenge before the PTAB and a favorable settlement prior to trial in the Eastern District of Pennsylvania. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a new chemical entity for the treatment of schizophrenia and bipolar I disorder—case settled favorably prior to trial. *
- Major pharmaceutical company in successfully defending the sale and use of a statin against accusations of patent infringement, seeking damages in excess of US$1 billion—summary judgment granted. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a new chemical entity for the treatment of non-small cell lung cancer—case settled favorably prior to trial. *
- Biopharmaceutical company in successfully defending a monoclonal antibody approved to treat multiple sclerosis. Defense resulted in a favorable ruling by the PTAB that denied institution in multiple proceedings. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a treatment for acne vulgaris—favorable settlement prior to trial. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a treatment for ulcerative colitis. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a low dose oral contraceptive—after a two-week trial, obtained a judgment upholding validity, affirmed on appeal. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a treatment for COPD. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a treatment for Alzheimer’s. *
- Pioneering pharmaceutical company in a Hatch-Waxman litigation involving a chewable oral contraceptive. *
*Reflects experience at previous employer
Perspectives
Credentials
Education
- J.D., University of North Carolina School of Law, 2012, high honors, Order of Coif
- M.S., Synthetic Organic Chemistry, University of Illinois at Urbana-Champaign, 2004
- B.S., Chemistry, Butler University, 2001,
cum laude
Admissions
- District of Columbia
- Maryland
- Federal Circuit